• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对以下内容的更正:加卡尼单抗治疗发作性偏头痛:3期研究(EVOLVE-1和EVOLVE-2)中偏头痛发作高频率与低频率的疗效亚组分析。

Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).

作者信息

Silberstein Stephen D, Stauffer Virginia L, Day Katie A, Lipsius Sarah, Wilson Maria-Carmen

机构信息

Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA.

Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, USA.

出版信息

J Headache Pain. 2019 Dec 27;20(1):118. doi: 10.1186/s10194-019-1069-x.

DOI:10.1186/s10194-019-1069-x
PMID:31881817
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6933678/
Abstract

After publication of our article [1] we were notified that the data presented in the upper row of Fig. 7 was inadvertently the least square mean change from baseline (standard error) at Month 6 rather than the overall average of Month 3 and Month 6. The figure legend and discussion of the data in the text were and are correct. The error was only in the upper row of Fig. 7. The legend for Fig. 7 did not require revision.

摘要

我们的文章[1]发表后,我们收到通知,图7上排所示数据无意中是第6个月时相对于基线的最小二乘均值变化(标准误差),而非第3个月和第6个月的总体平均值。图注以及文中对数据的讨论过去和现在都是正确的。错误仅存在于图7的上排。图7的图注无需修订。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5175/6933678/d1fc2364678d/10194_2019_1069_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5175/6933678/d1fc2364678d/10194_2019_1069_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5175/6933678/d1fc2364678d/10194_2019_1069_Fig1_HTML.jpg

相似文献

1
Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).对以下内容的更正:加卡尼单抗治疗发作性偏头痛:3期研究(EVOLVE-1和EVOLVE-2)中偏头痛发作高频率与低频率的疗效亚组分析。
J Headache Pain. 2019 Dec 27;20(1):118. doi: 10.1186/s10194-019-1069-x.
2
Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).加巴喷丁在发作性偏头痛中的疗效:3 期研究(EVOLVE-1 和 EVOLVE-2)中根据偏头痛发作频率高低的亚组分析。
J Headache Pain. 2019 Jun 28;20(1):75. doi: 10.1186/s10194-019-1024-x.
3
Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.加巴喷丁预防偏头痛发作的疗效评价:EVOLVE-1 随机临床试验。
JAMA Neurol. 2018 Sep 1;75(9):1080-1088. doi: 10.1001/jamaneurol.2018.1212.
4
Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.加巴喷丁在预防阵发性偏头痛中的疗效和安全性:EVOLVE-2 期 3 随机对照临床试验结果。
Cephalalgia. 2018 Jul;38(8):1442-1454. doi: 10.1177/0333102418779543. Epub 2018 May 31.
5
Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab.发作性偏头痛患者的功能测量:加奈徳珠单抗的一项双盲、随机、安慰剂对照 2b 期试验结果。
Headache. 2018 Sep;58(8):1225-1235. doi: 10.1111/head.13383. Epub 2018 Aug 14.
6
Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.加巴喷丁预防偏头痛发作的不同剂量与安慰剂的效果:一项随机临床试验。
JAMA Neurol. 2018 Feb 1;75(2):187-193. doi: 10.1001/jamaneurol.2017.3859.
7
Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.对《欧洲头痛联盟关于使用作用于降钙素基因相关肽或其受体的单克隆抗体预防偏头痛的指南》的勘误
J Headache Pain. 2019 May 23;20(1):58. doi: 10.1186/s10194-019-0972-5.
8
Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.A型肉毒杆菌毒素预防发作性偏头痛的疗效:一项随机、双盲、安慰剂对照试验的荟萃分析。
Pharmacotherapy. 2009 Jul;29(7):784-91. doi: 10.1592/phco.29.7.784.
9
Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study.加巴喷丁治疗发作性偏头痛患者的安全性:一项随机安慰剂对照的 2b 期剂量范围研究。
Cephalalgia. 2018 May;38(6):1015-1025. doi: 10.1177/0333102417747230. Epub 2018 Jan 8.
10
Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention.发作性和慢性偏头痛:打破优化治疗与预防的障碍
Headache. 2015 Mar;55 Suppl 2:103-22; quiz 123-6. doi: 10.1111/head.12505_2.

本文引用的文献

1
Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).加巴喷丁在发作性偏头痛中的疗效:3 期研究(EVOLVE-1 和 EVOLVE-2)中根据偏头痛发作频率高低的亚组分析。
J Headache Pain. 2019 Jun 28;20(1):75. doi: 10.1186/s10194-019-1024-x.